Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2008

View Archived Issues

Preclinical data on nucleoside polymerase inhibitors IDX-102, IDX-184 presented

Results from ASSIST-2 show efficacy of iclaprim in cSSSI

Met inhibitor JNJ-38877605 advanced to clinical evaluation for metastasized malignancies

SK inhibitor shows good pharmacokinetics and antitumor activity in preclinical studies

Novel Hsp90 inhibitor shows benefits in breast cancer models in vivo

Protherics reports results from phase IIb DEEP study of GSK's Digibind in preeclampsia

Agennix initiates phase II study of oral talactoferrin for severe sepsis

Amkor completes its phase I study of NEU-2000 in brain injury

FDA accepted Addrenex's NDA for CloniBID to treat hypertension

Spectrum reports positive results from phase IIb study of LHRH antagonist ozarelix in BPH

GSK to acquire Sirtris Pharmaceuticals for approximately USD 720 million

Cytheris initiates phase I clinical trial of CYT-107 in immunodeficient transplant recipients

MacroChem acquires Virium Pharmaceuticals

Alizyme reports negative results from phase III clinical trial of renzapride in IBS-C

Clinuvel announces results from its phase I studies of CUV-1647

PTC Therapeutics initiates phase IIb clinical trial of PTC-124 in DMD/BMD

European CHMP issues positive opinion for conditional approval of Tyverb

Volibris approved in E.U. for functional class II and III PAH

ACR-16 begins phase III for Huntington's disease

CHMP issues positive opinion for icatibant in HAE; FDA issues not approvable letter

CHMP issues positive opinions for two Merck medicines

Ligand initiates phase II LGD-4665 trial in idiopathic thrombocytopenic purpura

European Commission approves Viread for chronic hepatitis B

Schering-Plough/Merck receives not-approvable letter from FDA

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Data from ranibizumab AMD studies presented at the ARVO meeting

Recent Lilly and GSK patents describe new anxiolytic and antidepressant agents

Micellar formulation of calcineurin inhibitor voclosporin effective and well-tolerated in dry eye

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...